Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEAM-103 · 1 trial · 2 indications
Incidence of treatment-emergent AEs, serious AEs, severe AEs, AEs related to BEAM-103
| Arm | Type | Description |
|---|---|---|
| BEAM-103 Drug Product | EXPERIMENTAL | BEAM-103 is a monoclonal antibody that will be administered in single dose ascending dose cohorts as an intravenous infusion through the arm. |
| Placebo | PLACEBO_COMPARATOR | Normal Saline Solution will be administered as a matching place in single dose ascending dose cohorts as an intravenous infusion through the arm. |
| Name | Type | Description |
|---|---|---|
| BEAM-103 | DRUG | • BEAM-103 is a monoclonal antibody administered as a single intravenous dose |
| Placebo Comparator | DRUG | • The matching placebo comparator is administered as a single intravenous dose |
Inclusion Criteria: * Ages 18 to ≤55 years * Body mass index (BMI) of 18.5 to 25 kg/m2 * Morning neutrophil count ≥2.6 × 109 cells/L for Black/African American subjects or ≥3.5 ×109 cells/L for Caucasian/Other subjects * Baseline hemoglobin value of ≥14 g/dL for males and ≥12 g/dL for females * Bas...
BEAM-103 is an investigational small molecule being studied for use in healthy subjects. It is currently in a Phase 1 clinical trial to assess its safety, pharmacokinetics, and pharmacodynamics in healthy participants. The drug is not yet approved and remains in clinical development.
BEAM-103 targets CD117, a protein also known as c-Kit. This target is a receptor tyrosine kinase involved in cell signaling. The drug is designed to interact with this protein, though its full mechanism of action is still under investigation in clinical trials.
BEAM-103 is being developed by Beam Therapeutics Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol BEAM. The company is conducting a Phase 1 clinical trial of this investigational drug in healthy subjects.
BEAM-103 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety, pharmacokinetics, and pharmacodynamics in healthy subjects.
BEAM-103 is being studied in one active Phase 1 clinical trial with the identifier NCT07304791. This is a randomized, single-blind, placebo-controlled study enrolling 30 healthy subjects in the United Kingdom. The trial is currently recruiting participants aged 18 years and older.